Lol, quote, "lol"
Sunrise, FL – March 17, 2015 – Bioheart, Inc., a Florida Corporation (BHRT.OB), an emerging enterprise in the regenerative medicine / cellular therapy industry is pleased to announce, following the release of its Form 10-K Annual Report, key 2014 accomplishments including but not limited to:
1.A 2,040% increase in year over year revenues to $2.1 million in 2014 from $0.1 million in 2013,
2.A 28% decrease in year over year net loss to ($2.25) million in 2014 from ($3.14) million in 2013,
3.A 42% decrease in year over year cash used in operating activities to $1.1 million in 2014 from $1.9 million in 2013,
4.A 20% reduction ($2.3 million) in year over year current liabilities to $11.1 million at December 31, 2014 from $13.4 million at December 31, 2013, and
5.A 20% reduction in the Company’s working capital deficit.
“Bioheart is moving in the right direction,” said Mike Tomas, President and Chief Executive Officer. “We are extremely proud of what we have accomplished in 2014 and through an extraordinary effort have set the stage for continuing improvements in both income statement and balance sheet performance in 2015. In 2015, we will continue our efforts to reshape Bioheart into a growth oriented, profit generating company capable of delivering regenerative / cellular therapies and products globally while advancing our clinical development pipeline to market. In the coming months, we look forward to announcing new strategic relationships that will introduce new opportunities for growth as well as jump starting long delayed clinical programs. I extend my sincere thanks to Dr. William P. Murphy, Jr., our Chairman, our Board of Director, Kristin Comella, our Chief Scientific Officer, the Bioheart Team and most especially you, our shareholders for your continuing support, commitment and dedication to our Company. We are excited about Bioheart’s future and we look forward to keeping you posted on our progress.”
